Abstract
The objective of pancreas transplantation is to normalize the carbohydrate metabolism. This in turn may have some influence on the development of secondary complications: it may stabilize or even reverse some of the severe, progressive, and still life-threatening secondary diseases of diabetes mellitus. Pancreas transplantation should be considered at an earlier stage of the disease than it is at the moment, before the complications are too far advanced to be reversible. But for this to happen it has to be well established that normal glucose control can be achieved with a higher long-term success rate. Many different surgical techniques and immunosuppressive regimens have been used over the last decade, and survival rates have improved considerably, although they have not yet reached comparable results with kidney transplantation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Calne RY, McMaster P, Duffy TJ: Technical observations in segmental pancreas allografting: Observations on pancreatic blood flow. Transplant Proc 12:51–54, 1980.
Corry R, Ngheim DD, Schulak JA, Bentel WD Gonwa TA: Surgical treatment of diabetic nephropathy with simultaneous pancreatic, duodenal and renal transplantation. Surg Gynecol Obstet 162:547–555, 1986.
Corry R, Nghiem DD, Gonwa TA: Critical analysis of mortality and graft loss following simultaneous renal pancreatic duodenal transplantation. Transplant Proc 19:2305–2306, 1987.
Landgraf R, Landgraf-Leurs MMC, Burg D, Kampik A, Castro LA, Abendroth A, Illner WD, Land W: Long term follow-up of segmental pancreas transplantation in type I diabetes. Transplant Proc 18:1118–1124, 1986.
Brekke IB, Dyrbekke D, Jakobsen A, Jervell J, Sodal G, Flatmark A: Improved pancreas graft survival in combined pancreatic and renal transplantation. Transplant Proc 18:1125–1126, 1986.
Tyden G, Mellgren A, Brattstrom C, Ost L, Gunnarsson R, Ostman J, Groth CG: Stockholm experience with 32 combined renal and segmental pancreatic transplants. Transplant Proc 18:1114–1117, 1986.
Tyden G, Lundgren G, Ost L, Gunnarsson R, Ostman J, Groth CG: Are pancreatic grafts prone to rejection? Transplant Proc 18:27–29, 1986.
Calne RY, Brons, IGM: Observations on para-topic segmental pancreas grafting with splenic venous drainage. Transplant Proc 18:340–341, 1985.
Brattstrom C, Tyden G, Lundgren G, Ost L, Groth CG: Studies on the exocrine secretion of segmental pancreatic grafts. Transplant Proc 19:2332–2335, 1987.
Steiner E, Klima J, Niederwieser D, Herold M, Margreiter R: Monitoring of the pancreatic allograft by analysis of exocrine secretion. Transplant Proc 19:2336–2338, 1987.
Sollinger HW, Kalayoglu M, Hoffmann RM, Beizer F: Quadruple immunosupopressive therapy in whole pancreas transplantation. Transplant Proc (in press).
Tom WW, Munda R, First MR, Alexander JW: Physiological consequences of pancreatic allograft exocrine drainage into the urinary tract. Transplant Proc 19: 2339–2342, 1987.
Land W, Landgraf R, Illner WD, et al: Improved results in combined segmental pancreatic and renal transplantation in diabetic patients under cyclosporine therapy. Transplant Proc 17:317–324, 1985.
Dubernard JM, Traeger J, Piatti PM, et al: Report of 54 human segmental pancreatic allografts prepared by duct obstruction with neoprene. Transplant Proc 17:312–314, 1985.
Traeger J, Monti LD, Dubernard JM, Touraine JL, Piatti PM, Bosi E, Cantarovich D, Lefrancois N, Secchi A, Pozza G: Metabolic studies and follow-up of degenerative complications in patients with a long-term functioning pancreatic graft (more than 1 year). Transplant Proc 18:1139–1140, 1986.
Pozza G, Bosi E, Secchi A, Piatti PM, Touraine JL, Gelet A, Pontiroli A, Dubernard JM, Traeger J: Metabolic control of type I (insulin dependent diabetes) after pancreas transplantation. Br Med J 291:510–513, 1985.
Tyden G, Brattstrom C, Gunnarsson R, Lundgren G, Ost L, Ostman J, Groth CG: Metabolic control 2 months to 4.5 years after pancreatic transplantation with special reference to the role of CyA. Transplant Proc 19:2294–2296, 1987.
Sutherland DER: Current status of transplantation of the pancreas. In Advances in Surgery. Chicago: Year Book, 1986.
Wilczek H, Gunnarsson R, Felig P, Wahren J, Groth CG: Normalization of hepatic glucose regulation following heterotopic pancreatic transplantation in humans. Transplant Proc 17:315–316, 1985.
Calne RY: Paratopic segmental pancreas grafting: A technique with portal venous drainage. Lancet 1:595–597, 1984.
Engfelt P, Tyden G, Gunnarsson R, Ostman J, Groth CG: Impaired glucose tolerance with CyA. Transplant Proc 18:65–66, 1986.
Canny CLB, Kohner EM, Trautman J, Puklin J, Morse P, for the Kroc Collaborative Study Group: Comparison of stero fundus photographs in patients with insulin-dependent diabetes during conventional insulin treatment or continuous subcutaneous insulin infusion. Diabetes 34 (suppl 3): 50–55, 1985.
Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T, and the Steno group: Two years’ experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34 (suppl 3): 74–79, 1985.
Bohman SO, Tyden G, Wilczek H, et al: Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes 34: 306–308, 1985.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Brons, I.G.M., Calne, R.Y. (1988). Clinical Posttransplant Followup. In: Toledo-Pereyra, L.H. (eds) Pancreas Transplantation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1735-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1735-7_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8976-0
Online ISBN: 978-1-4613-1735-7
eBook Packages: Springer Book Archive